Compare
Aura Biosciences, Inc. vs SAB Biotherapeutics, Inc. vs Cabaletta Bio, Inc. vs Caribou Biosciences, Inc.
| Latest fiscal year | Aura Biosciences, Inc. AURA | SAB Biotherapeutics, Inc. SABSRevenue covers only part of its income (partial revenue) | Cabaletta Bio, Inc. CABA | Caribou Biosciences, Inc. CRBU |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | n/a | $11.16M |
| Revenue growth (YoY) | n/a | n/a | n/a | +11.7% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | n/a | n/m |
| Net margin | n/a | n/a | n/a | n/m |
| Net income | -$106.19M | $13.27M | -$167.86M | -$148.12M |
| EPS (Diluted) | -$1.76 | -$0.79 | -$2.10 | -$1.59 |
| Operating cash flow | -$84.74M | -$44.78M | -$131.08M | -$110.99M |
| Free cash flow | -$85.19M | -$45.71M | -$132.31M | -$112.35M |
| Cash & equivalents | $59.52M | $10.50M | $82.98M | $12.36M |
| Total assets | $169.43M | $172.81M | $165.08M | $175.37M |
| Total liabilities | $32.52M | $21.32M | $53.03M | $53.19M |
| Shareholders' equity | $136.91M | $151.49M | $112.05M | $122.17M |
| Return on year-end equity | -77.6% | 8.8% | -149.8% | -121.2% |
| Shares outstanding | 63.59M | 47.61M | 100.48M | 95.14M |
Revenue, most recent five fiscal years
| Fiscal year | Aura Biosciences, Inc. | SAB Biotherapeutics, Inc. | Cabaletta Bio, Inc. | Caribou Biosciences, Inc. |
|---|---|---|---|---|
| Latest | n/a | n/a | n/a | $11.16M Ended 2025-12-31 |
| 1 year earlier | n/a | n/a | n/a | $9.99M Ended 2024-12-31 |
| 2 years earlier | n/a | n/a | n/a | $34.48M Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | n/a | $13.85M Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | n/a | $9.60M Ended 2021-12-31 |